The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

The following is a summary of “Treating chronic kidney disease in Danish primary care: results from the observational ATLAS study,” published in the February 2025 issue of BMC Primary Care by ...

Body weight cycling in type 1 diabetes is associated with increased risk of chronic kidney disease. Maintaining stable weight ...

Weight cycling is a pattern in which individuals repeatedly lose and regain body weight. Researchers have found in a new ...

Investigators compared the outcomes of patients with type 2 diabetes who continued versus stopped metformin after progressing to stage 4 chronic kidney disease.

INNOVATE Corp. surged 150% after its subsidiary MediBeacon received FDA approval for its TGFR system. See why I rate VATE ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

A post hoc analysis of trial data published in Diabetes Care found that adults with type 2 diabetes receiving tirzepatide ...

For individuals with type 1 diabetes, intraindividual body weight variability, or body weight cycling, is associated with an increased risk for renal events.

The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...